Anti-PRTFDC1 antibody

Cat.#: 100645

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-PRTFDC1 antibody
  • Documents
  • Description
    Mouse monoclonal to PRTFDC1
  • Tested applications
    WB
  • Species reactivity
    Human PRTFDC1
  • Alternative names
    Gm13377 antibody; HHGP antibody; OTTMUSG00000011667 antibody; phosphoribosyl transferase domain containing 1 antibody; phosphoribosyltransferase domain containing 1 pseudogene antibody; phosphoribosyltransferase domain-containing protein 1 antibody; Prtfdc1 antibody; PRTFDC1 antibody; RP11-129O7.1 antibody
  • Immunogen
  • Isotype
    Mouse IgG
  • Preparation
    This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human PRTFDC1 (rh PRTFDC1; Q9NRG1-1; Met1-Val225). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% treha
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    WB: 20-30 μg/ml

  • Validations

    PRTFDC1 Antibody, Mouse MAb, Western blot

    PRTFDC1 Antibody, Mouse MAb, Western blot

  • Background
    PRTFDC1 is a member of the purine/pyrimidine phosphoribosyltransferase family. It can bind GMP, IMP and alpha-D-5-phosphoribosyl 1-pyrophosphate (PRPP). The epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis. PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse and has important implications for unraveling the molecular etiology of lesch-Nyhan disease(LND). LND is a severe X-linked neurological disorder caused by a deficiency of hypoxanthine phosphoribosyltransferase. PRTFDC1 has a low, barely measurable phosphoribosyltransferase activity (in vitro).
  • References
    • Welin M. et al., 2010, FEBS J. 277 (23): 4920-30.
    • Keebaugh AC. et al., 2011, PLoS One. 6 (7): e22381.
    • Suzuki E. et al., 2007, Oncogene. 26 (57): 7921-32.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"